{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '6b. The proportion of participants in each', 'vaccination group achieving', 'seroconversion following IIV4 (an HAI titer', '> 1:40 following IIV4 if the baseline titer is <', '1:10 or a four-fold rise in HAI titer if the', 'baseline titer is > 1:10) for each IIV4', 'antigen', '6c. The geometric mean HAI titer (GMT)', 'for each IIV4 antigen pre- and post-IIV4 in', 'each vaccination group', '6d. The geometric mean fold rise (GMFR)', 'in HAI titer for each vaccination group', '7. To assess serum antibody levels to', '7a. *Exploratory outcome measures', 'SARS-CoV-2 antigens*', 'regarding serum antibody analyses will be', 'included in a future protocol amendment.', '3 STUDY DESIGN', '3.1 Main study design', 'This study is a prospective, randomized, clinical trial to assess the safety of simultaneous', 'versus sequential administration of mRNA COVID-19 and IIV4 vaccines in 450 persons age >12', 'years enrolled at Duke University Medical Center (Lead Contractor), Johns Hopkins University', \"(Contributing Contractor), and Cincinnati Children's Hospital Medical Center (Contributing\", 'Contractor). Participants will be enrolled in the 2021-2022 influenza season. Adults and', 'adolescents will be enrolled who have not received their influenza vaccine during the influenza', 'season during which they are recruited and are either receiving their third dose of mRNA', 'COVID-19 vaccine (18 years of age or older) or are receiving their primary two-dose mRNA', 'COVID-19 vaccine series (12 years of age or older). Health, demographic and health-related', 'quality of life (HRQOL) data will be collected from study participants at baseline. All participants', 'receiving an mRNA COVID-19 vaccine on Day 1 (Visit 1) will be randomized to receive', 'quadrivalent inactivated influenza vaccine (IIV4) or placebo. Persons aged <65 years will', 'receive standard dose IIV4 (SD-IIV4) or saline placebo injection. Persons aged >65 years will', 'receive high-dose IIV4 (HD-IIV4) or saline placebo injection. Participants will receive the', 'vaccines in an observer-blinded manner on the same day as they receive mRNA COVID-19', 'vaccine. Fourteen days later (Visit 2) those who received IIV4 at Visit 1 will receive placebo and', 'those who received placebo on at Visit 1 will receive IIV4 (SD-IIV4 or HD-IIV4, depending upon', 'age). Participants will then receive a second mRNA COVID-19 vaccine (Visit 3), if applicable,', 'and according to the recommended schedule for vaccination for the respective mRNA COVID-', '19 vaccine product used.', 'With Day 1 serving as the initial day of vaccination, participants will be followed through Day 7', '(total 7 days) for solicited symptoms of reactogenicity as described in Section 5.4. HRQOL data', 'will be collected during this time period. Solicited reactogenicity events will also be monitored', 'through Day 7 (total 7 days) following Visit 2 (all participants) and Visit 3 (only those participants', 'receiving primary 2-dose COVID-19 vaccine series). Participants will also be followed for 7', '21']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'days after each vaccination visit for unsolicited adverse events, through Day 120 for serious', 'adverse events (SAEs) and through Day 120 for adverse events of special interest (AESI), as', 'described in Section 5.4.', '3.2 Laboratory Studies', '3.2.1 Influenza Hemagglutination Inhibition Assay', 'mRNA COVID-19 vaccine na\u00efve participants will have blood draws on Day 1 (before', 'vaccination) and Day 21 (Pfizer/BioNTech mRNA vaccine) or Day 29 (Moderna mRNA post-IIV4', 'vaccination to be stored for serum hemagglutination inhibition (HAI) antibody titers. Those', 'receiving a 3rd dose of mRNA COVID-19 vaccine will have blood draws on Day 1 (before', 'vaccination) and Day 29. HAI antibody titers will be compared between groups receiving', 'COVID-19 and IIV4 simultaneously or sequentially for each of the four influenza vaccine strains', 'contained in the respective vaccines for that season. Participants will not receive individual HAI', 'antibody titer results; these are not routinely used in clinical practice.', '3.2.2 SARS-CoV-2 Antibody Assay', 'Participants will have blood draws on day 1 (before vaccination) as noted in 3.2.1', 'Serum will be assayed for the presence of SARS-CoV-2 antibody using the AdviseDx SARS-', 'CoV-2 IgG Il assay and the Alinity I SARS-CoV-2 IgG assay. The assays are intended for use', 'as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2 indicating', 'recent or prior infection. Serologic testing will be completed in periodic batches throughout the', 'course of the study and will therefore not be available in real-time or for use in clinical decision-', \"making. The current tests described above are allowed under the FDA's Emergency Use\", 'Authorization during the COVID-19 pandemic. Duke will share participant results with each', 'study site as permitted by FDA and CDC. Study sites may share results with participant as', 'permitted by FDA, CDC, and local site regulations.', 'In', 'addition, pending funding, we are proposing to conduct quantitative SARS-CoV-2 neutralizing', 'antibody titers in a pseudovirus assay to assess antibody levels.', '3.2.3 Future studies', 'In addition to the specified analyses described thus far, there may be other tests or assays that', 'have yet to be identified that may be important for interpreting our study findings or of relevance', 'to vaccine outcomes. Additional laboratory assays may test for antibodies against other bacteria', 'or viruses, markers of inflammation, or used in research on the health of the participants.', 'Specimens banked for use in other studies will be linked to information (including identifying', 'information) that participants provided to the study. Subjects must agree to potential future use', 'of samples in order to be in the study. Because it is unknown if future testing will be of any', 'utility, results of future testing will not be provided.', '4', 'STUDY ENROLLMENT AND WITHDRAWAL', '4.1 Subject Inclusion Criteria', 'Subjects who meet all of the following criteria will be eligible to participate in this', 'interventional study.', '22']\n\n###\n\n", "completion": "END"}